This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Sheng JY , Movva S
Systemic Therapy for Advanced Soft Tissue Sarcoma
Surg Clin North Am. 2016 Oct;96(5) :1141-56
PMID: 27542647 URL: http://www.ncbi.nlm.nih.gov/pubmed/27542647
AbstractSoft tissue sarcomas are rare tumors that present with distant metastasis in up to 10% of patients. Survival has improved significantly because of advancements in histologic classification and improved management approaches. Older agents such as doxorubicin, ifosfamide, gemcitabine, and paclitaxel continue to demonstrate objective response rates from 18% to 25%. Newer agents such as trabectedin, eribulin, aldoxorubicin, and olaratumab have demonstrated improvements in progression-free survival, overall survival, or toxicity profiles. Future studies on treatment of advanced soft tissue sarcoma will continue to concentrate on reducing toxicity, personalization of therapy, and targeting novel pathways.
NotesSheng, Jennifer Y Movva, Sujana Review United States Surg Clin North Am. 2016 Oct;96(5):1141-56. doi: 10.1016/j.suc.2016.06.006.